Olaparib (BioDeep_00000858507)
代谢物信息卡片
Olaparib (AZD2281, Ku-0059436)
化学式: C24H23FN4O3 (434.1754)
中文名称: 奥拉帕尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
InChI: InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XK - Poly (adp-ribose) polymerase (parp) inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor
D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors
D004791 - Enzyme Inhibitors
C471 - Enzyme Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:83766
- KEGGdrug: D09730
- PubChem: 23725625
- DrugBank: DB09074
- ChEMBL: CHEMBL521686
- CAS: 1021843-02-6
- CAS: 763113-22-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Lian Wang, Bing Xiong, Wei Lu, Yujie Cheng, Jihui Zhu, Guihai Ai, Xiaojie Zhang, Xiuni Liu, Zhongping Cheng. Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2024 May; 174(?):116474. doi:
10.1016/j.biopha.2024.116474. [PMID: 38518604] - Dong Yang, Yanbin Zhang, Ping Gong, Sijia Ren, Yale Gan, Feiran Liu, Chao Wang, Xinxin Zhao, Renzi Liu, Wenpei Bai. Secondary cytoreductive surgery followed by olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
2024 Feb; 50(2):107950. doi:
10.1016/j.ejso.2024.107950. [PMID: 38215549] - Yang Liu, Zhongkun Guo, Fangfang Lang, Jie Li, Jie Jiang. Anticancer Effect of Active Component of Astragalus Membranaceus Combined with Olaparib on Ovarian Cancer Predicted by Network-Based Pharmacology.
Applied biochemistry and biotechnology.
2023 Mar; ?(?):. doi:
10.1007/s12010-023-04462-5. [PMID: 36976504] - Yang Zhao, Kehui Zhou, Xiangyu Xia, Yajie Guo, Li Tao. Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells.
Cell cycle (Georgetown, Tex.).
2023 Jan; 22(2):200-212. doi:
10.1080/15384101.2022.2111769. [PMID: 35959961] - Sangsang Tang, Yuanming Shen, Xinyi Wei, Zhangjin Shen, Weiguo Lu, Junfen Xu. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Cell death & disease.
2022 09; 13(9):826. doi:
10.1038/s41419-022-05257-y. [PMID: 36163324] - Masatoshi Takagi, Chitose Ogawa, Tomoko Iehara, Yuki Aoki-Nogami, Eri Ishibashi, Minoru Imai, Toshimi Kimura, Masashi Nagata, Masato Yasuhara, Mitsuko Masutani, Kenichi Yoshimura, Daisuke Tomizawa, Atsushi Ogawa, Kan Yonemori, Aoi Morishita, Satoshi Miyamoto, Junko Takita, Tetsuro Kihara, Kiyoshi Nobori, Kazuhisa Hasebe, Fuyuki Miya, Sadakatsu Ikeda, Yoko Shioda, Kimikazu Matsumoto, Junya Fujimura, Shuki Mizutani, Tomohiro Morio, Hajime Hosoi, Ryuji Koike. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
Cancer.
2022 08; 128(15):2949-2957. doi:
10.1002/cncr.34270. [PMID: 35593736] - Yoo-Kyung Song, Min-Ju Kim, Min-Soo Kim, Ji Hun Lee, Suk-Jae Chung, Jin Sook Song, Yoon-Jee Chae, Kyeong-Ryoon Lee. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2022 Jun; 173(?):106177. doi:
10.1016/j.ejps.2022.106177. [PMID: 35341895] - Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W G Wijnhoven, Adina M Hughes, Joe Gerrard, Gemma N Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A Young, Mark J O'Connor, Alan Lau. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Cancer research.
2022 03; 82(6):1140-1152. doi:
10.1158/0008-5472.can-21-2997. [PMID: 35078817] - Stephan Ursprung, Helen Mossop, Ferdia A Gallagher, Evis Sala, Richard Skells, Jamal A N Sipple, Thomas J Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y Warren, John Stone, Tim Eisen, James Wason, Sarah J Welsh, Grant D Stewart. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
BMC cancer.
2021 Nov; 21(1):1238. doi:
10.1186/s12885-021-08965-4. [PMID: 34794412] - Zhixia Chen, Yihui Chen, Xianwei Jin, Ying Liu, Zhenzhen Shao, Quan Li. Olaparib attenuates sepsis-induced acute multiple organ injury via ERK-mediated CD14 expression.
Experimental biology and medicine (Maywood, N.J.).
2021 09; 246(17):1948-1958. doi:
10.1177/15353702211015620. [PMID: 34053236] - Huan Long, Xiaolong Hu, Baolin Wang, Quan Wang, Rong Wang, Shumeng Liu, Fei Xiong, Zhenzhou Jiang, Xiao-Qi Zhang, Wen-Cai Ye, Hao Wang. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Journal of medicinal chemistry.
2021 08; 64(16):12089-12108. doi:
10.1021/acs.jmedchem.1c00735. [PMID: 34404206] - Cen Zhao, Dawei Yang, Yuchen Ye, Zhenzhong Chen, Tifan Sun, Jiawei Zhao, Kai Zhao, Na Lu. Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.
Biochemical pharmacology.
2021 08; 190(?):114648. doi:
10.1016/j.bcp.2021.114648. [PMID: 34111425] - Wenchao Li, Bowen Pan, Yang Shi, Meiying Wang, Tianjiao Han, Qing Wang, Guifang Duan, Hongzheng Fu. Identification of poly(ADP-ribose)polymerase 1 and 2 (PARP1/2) as targets of andrographolide using an integrated chemical biology approach.
Chemical communications (Cambridge, England).
2021 Jun; 57(51):6308-6311. doi:
10.1039/d1cc02272e. [PMID: 34075974] - Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwenaelle Gravis, Florence Joly, Joan Carles, Aude Fléchon, Pablo Maroto, Daniel Petrylak, Frédéric Rolland, Natalie Cook, Arjun V Balar, Srikala S Sridhar, Matthew D Galsky, Petros Grivas, Alain Ravaud, Robert Jones, Jan Cosaert, Darren Hodgson, Iwanka Kozarewa, Richard Mather, Robert McEwen, Florence Mercier, Dónal Landers. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Nature medicine.
2021 05; 27(5):793-801. doi:
10.1038/s41591-021-01317-6. [PMID: 33941921] - Qi Zhang, Yingkun Xu, Zhiyu Zhang, Jianyi Li, Qinghua Xia, Yougen Chen. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Gene.
2021 Feb; 769(?):145243. doi:
10.1016/j.gene.2020.145243. [PMID: 33069804] - M A C Bruin, C M Korse, B van Wijnen, V M T de Jong, S C Linn, B van Triest, H Rosing, J H Beijnen, D van den Broek, A D R Huitema. A real or apparent decrease in glomerular filtration rate in patients using olaparib?.
European journal of clinical pharmacology.
2021 Feb; 77(2):179-188. doi:
10.1007/s00228-020-03070-0. [PMID: 33319340] - Catherine Hanna, Kathreena M Kurian, Karin Williams, Colin Watts, Alan Jackson, Ross Carruthers, Karen Strathdee, Garth Cruickshank, Laurence Dunn, Sara Erridge, Lisa Godfrey, Sarah Jefferies, Catherine McBain, Rebecca Sleigh, Alex McCormick, Marc Pittman, Sarah Halford, Anthony J Chalmers. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Neuro-oncology.
2020 12; 22(12):1840-1850. doi:
10.1093/neuonc/noaa104. [PMID: 32347934] - David J VanderWeele, Maha Hussain. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
Clinical advances in hematology & oncology : H&O.
2020 Dec; 18(12):808-815. doi:
NULL. [PMID: 33406057] - Ignacio Romero, M Jesús Rubio, Manuel Medina, Xavier Matias-Guiu, Maria Santacana, Juan-Antonio Schoenenberger, Eva Maria Guerra, Alfonso Cortés, Lucas Minig, Pluvio Coronado, Juan Fernando Cueva, Lourdes Gómez, Andrea Malfettone, Miguel Sampayo, Antonio Llombart-Cussac, Andrés Poveda. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
Gynecologic oncology.
2020 12; 159(3):721-731. doi:
10.1016/j.ygyno.2020.09.013. [PMID: 32988624] - Neelima Vidula, Taronish Dubash, Michael S Lawrence, Antoine Simoneau, Andrzej Niemierko, Erica Blouch, Becky Nagy, Whijae Roh, Brian Chirn, Brittany A Reeves, Giuliana Malvarosa, Jochen Lennerz, Steven J Isakoff, Dejan Juric, Douglas Micalizzi, Seth Wander, Laura Spring, Beverly Moy, Kristen Shannon, Jerry Younger, Richard Lanman, Mehmet Toner, A John Iafrate, Gad Getz, Lee Zou, Leif W Ellisen, Shyamala Maheswaran, Daniel A Haber, Aditya Bardia. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 09; 26(18):4852-4862. doi:
10.1158/1078-0432.ccr-20-0638. [PMID: 32571788] - Christian Rolfo, Nicolas Isambert, Antoine Italiano, L Rhoda Molife, Jan H M Schellens, Jean-Yves Blay, Thomas Decaens, Rebecca Kristeleit, Olivier Rosmorduc, Regina Demlova, Myung-Ah Lee, Alain Ravaud, Katerina Kopeckova, Maria Learoyd, Wendy Bannister, Gershon Locker, Judith de Vos-Geelen. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
British journal of clinical pharmacology.
2020 09; 86(9):1807-1818. doi:
10.1111/bcp.14283. [PMID: 32227355] - Jean-David Fumet, Emeric Limagne, Marion Thibaudin, Caroline Truntzer, Aurélie Bertaut, Emilie Rederstorff, Francois Ghiringhelli. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
BMC cancer.
2020 Aug; 20(1):748. doi:
10.1186/s12885-020-07253-x. [PMID: 32778095] - Amy L Winship, Meaghan Griffiths, Carolina Lliberos Requesens, Urooza Sarma, Kelly-Anne Phillips, Karla J Hutt. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Human reproduction (Oxford, England).
2020 08; 35(8):1864-1874. doi:
10.1093/humrep/deaa128. [PMID: 32604417] - Akbar Ahmad, Aline Haas De Mello, Bartosz Szczesny, Gábor Törö, Michela Marcatti, Nadiya Druzhyna, Lucas Liaudet, Stefano Tarantini, Reinaldo Salomao, Francisco Garcia Soriano, Csaba Szabo. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
Shock (Augusta, Ga.).
2020 05; 53(5):653-665. doi:
10.1097/shk.0000000000001402. [PMID: 31274831] - Guosheng Su, Lihua Qin, Xiaoye Su, Chuanmin Tao, Yesheng Wei. Gender-dependent pharmacokinetics of olaparib in rats determined by ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Biomedical chromatography : BMC.
2020 Mar; 34(3):e4791. doi:
10.1002/bmc.4791. [PMID: 31899538] - Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Claudia Carella, Paolo Scollo, Viola Ghizzoni, Francesco Raspagliesi, Marilena Di Napoli, Enrica Mazzoni, Claudia Marchetti, Alice Bergamini, Michele Orditura, Giorgio Valabrega, Giovanni Scambia, Giuseppa Maltese, Elisabetta De Matteis, Cinzia Cardalesi, Vera Loizzi, Serena Boccia, Emanuele Naglieri, Giuseppa Scandurra, Sandro Pignata. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecologic oncology.
2020 01; 156(1):38-44. doi:
10.1016/j.ygyno.2019.10.023. [PMID: 31699415] - Cheng-Zhi Gao, Wei Dong, Zhi-Wen Cui, Qiong Yuan, Xia-Min Hu, Qing-Ming Wu, Xianlin Han, Yao Xu, Zhen-Li Min. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Journal of enzyme inhibition and medicinal chemistry.
2019 Dec; 34(1):150-162. doi:
10.1080/14756366.2018.1530224. [PMID: 30427217] - Huan Wang, Chenyu Mao, Ning Li, Liping Sun, Yulong Zheng, Nong Xu. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
Medicine.
2019 Oct; 98(40):e17443. doi:
10.1097/md.0000000000017443. [PMID: 31577767] - Lilla Nagy, Boglárka Rauch, Noémi Balla, Gyula Ujlaki, Gréta Kis, Omar Abdul-Rahman, Endre Kristóf, Adrienn Sipos, Miklós Antal, Attila Tóth, Tamás Debreceni, Ambrus Horváth, Tamás Maros, Péter Csizmadia, Tamás Szerafin, Péter Bai. Olaparib induces browning of in vitro cultures of human primary white adipocytes.
Biochemical pharmacology.
2019 09; 167(?):76-85. doi:
10.1016/j.bcp.2019.06.022. [PMID: 31251940] - Christian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, L Rhoda Molife, Jan H M Schellens, Jacques De Grève, Luc Dirix, Peter Grundtvig-Sørensen, Guy Jerusalem, Karin Leunen, Morten Mau-Sørensen, Ruth Plummer, Maria Learoyd, Wendy Bannister, Anitra Fielding, Alain Ravaud. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Clinical pharmacokinetics.
2019 09; 58(9):1165-1174. doi:
10.1007/s40262-019-00754-4. [PMID: 30877569] - E Bayart, A Flacco, O Delmas, L Pommarel, D Levy, M Cavallone, F Megnin-Chanet, E Deutsch, V Malka. Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein.
Scientific reports.
2019 07; 9(1):10132. doi:
10.1038/s41598-019-46512-1. [PMID: 31300704] - Akbar Ahmad, Juliana de Camargo Vieira, Aline Haas de Mello, Thais Martins de Lima, Suely Kubo Ariga, Denise Frediani Barbeiro, Hermes Vieira Barbeiro, Bartosz Szczesny, Gábor Törö, Nadiya Druzhyna, Elisa B Randi, Michela Marcatti, Tracy Toliver-Kinsky, András Kiss, Lucas Liaudet, Reinaldo Salomao, Francisco Garcia Soriano, Csaba Szabo. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Pharmacological research.
2019 07; 145(?):104263. doi:
10.1016/j.phrs.2019.104263. [PMID: 31071432] - Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Alienor Berges, Tsveta Milenkova, Nidal Al-Huniti, Helen Tomkinson, Hongmei Xu. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Clinical pharmacokinetics.
2019 05; 58(5):615-625. doi:
10.1007/s40262-018-0714-x. [PMID: 30357650] - Roberta Ottria, Alessandro Ravelli, Matteo Miceli, Sara Casati, Marica Orioli, Pierangela Ciuffreda. Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS.
Molecules (Basel, Switzerland).
2019 Mar; 24(5):. doi:
10.3390/molecules24050989. [PMID: 30862103] - Yoo-Kyung Song, Ji Eun Park, Yunseok Oh, Sungwoo Hyung, Yoo-Seong Jeong, Min-Soo Kim, Wooin Lee, Suk-Jae Chung. Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib.
The Journal of pharmacology and experimental therapeutics.
2019 01; 368(1):79-87. doi:
10.1124/jpet.118.250225. [PMID: 30396915] - Xiao-Long Hu, Jia-Hao Feng, Thi-Anh Pham, Hai-Yan Ma, Ming-Xi Ma, Rui Song, Wei Shen, Fei Xiong, Xiao-Qi Zhang, Wen-Cai Ye, Hao Wang. Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
Phytomedicine : international journal of phytotherapy and phytopharmacology.
2018 Nov; 50(?):88-98. doi:
10.1016/j.phymed.2018.09.012. [PMID: 30466996] - Yi Ma, Lijie He, Qianwen Huang, Shuang Zheng, Zhiqiang Zhang, Hongshi Li, Shuang Liu. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
BMC medical genetics.
2018 10; 19(1):185. doi:
10.1186/s12881-018-0703-9. [PMID: 30333000] - Ni Zhen, Lei Jin, Ji Ma, Jiabei Zhu, Song Gu, Jing Wang, Qiuhui Pan, Xiaorong Ni, Min Xu. Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage.
Anti-cancer drugs.
2018 09; 29(8):756-766. doi:
10.1097/cad.0000000000000646. [PMID: 29952772] - Claire Pressiat, Huu-Hien Huynh, Alain Plé, Hélène Sauvageon, Isabelle Madelaine, Cécile Chougnet, Christine Le Maignan, Samia Mourah, Lauriane Goldwirt. Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Therapeutic drug monitoring.
2018 06; 40(3):337-343. doi:
10.1097/ftd.0000000000000497. [PMID: 29474275] - Akbar Ahmad, Gabor Olah, David N Herndon, Csaba Szabo. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
British journal of pharmacology.
2018 01; 175(2):232-245. doi:
10.1111/bph.13735. [PMID: 28146604] - Alex McCormick, Helen Swaisland. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Oct; 47(10):903-915. doi:
10.1080/00498254.2016.1241449. [PMID: 27684210] - Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston, Dana-Adriana Botesteanu, Janis M Taube, Elizabeth Thompson, Aleksandra Ogurtsova, Haiying Xu, Jeffers Nguyen, Tony W Ho, William D Figg, Elise C Kohn. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017 Jul; 35(19):2193-2202. doi:
10.1200/jco.2016.72.1340. [PMID: 28471727] - Anne L van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John G Clohessy, G Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi, Srinivas Sridhar. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
Molecular cancer therapeutics.
2017 07; 16(7):1279-1289. doi:
10.1158/1535-7163.mct-16-0740. [PMID: 28500233] - Arimichi Okazaki, Paulo A Gameiro, Danos Christodoulou, Laura Laviollette, Meike Schneider, Frances Chaves, Anat Stemmer-Rachamimov, Stephanie A Yazinski, Richard Lee, Gregory Stephanopoulos, Lee Zou, Othon Iliopoulos. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
The Journal of clinical investigation.
2017 May; 127(5):1631-1645. doi:
10.1172/jci87800. [PMID: 28346230] - Karim Gariani, Dongryeol Ryu, Keir J Menzies, Hyon-Seung Yi, Sokrates Stein, Hongbo Zhang, Alessia Perino, Vera Lemos, Elena Katsyuba, Pooja Jha, Sandrine Vijgen, Laura Rubbia-Brandt, Yong Kyung Kim, Jung Tae Kim, Koon Soon Kim, Minho Shong, Kristina Schoonjans, Johan Auwerx. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
Journal of hepatology.
2017 01; 66(1):132-141. doi:
10.1016/j.jhep.2016.08.024. [PMID: 27663419] - Michael McMahon, Tania G Frangova, Colin J Henderson, C Roland Wolf. Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse.
Molecular cancer research : MCR.
2016 12; 14(12):1195-1203. doi:
10.1158/1541-7786.mcr-16-0108. [PMID: 27604276] - Kan Yonemori, Kenji Tamura, Makoto Kodaira, Koshi Fujikawa, Tamotsu Sagawa, Taito Esaki, Tsuyoshi Shirakawa, Fumihiko Hirai, Yuki Yokoi, Toshio Kawata, Ben Hatano, Yasuo Takahashi. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Cancer chemotherapy and pharmacology.
2016 Sep; 78(3):525-31. doi:
10.1007/s00280-016-3106-7. [PMID: 27422301] - Marklie Munroe, Jill Kolesar. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2016 Jul; 73(14):1037-41. doi:
10.2146/ajhp150550. [PMID: 27385701] - Mateusz Rytelewski, Saman Maleki Vareki, Lingegowda S Mangala, Larissa Romanow, Dahai Jiang, Sunila Pradeep, Christian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Rene Figueredo, Peter J Ferguson, Mark Vincent, Anil K Sood, James D Koropatnick. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Oncotarget.
2016 Apr; 7(15):20825-39. doi:
10.18632/oncotarget.7883. [PMID: 26959114] - Filip Zmuda, Gaurav Malviya, Adele Blair, Marie Boyd, Anthony J Chalmers, Andrew Sutherland, Sally L Pimlott. Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
Journal of medicinal chemistry.
2015 Nov; 58(21):8683-93. doi:
10.1021/acs.jmedchem.5b01324. [PMID: 26469301] - Ruth Plummer, Helen Swaisland, Karin Leunen, Carla M L van Herpen, Guy Jerusalem, Jacques De Grève, Martijn P Lolkema, Patricia Soetekouw, Morten Mau-Sørensen, Dorte Nielsen, James Spicer, Anitra Fielding, Karen So, Wendy Bannister, L Rhoda Molife. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology.
2015 Oct; 76(4):723-9. doi:
10.1007/s00280-015-2836-2. [PMID: 26242220] - Christian Rolfo, Helen Swaisland, Karin Leunen, Annemie Rutten, Patricia Soetekouw, Sarah Slater, Henk M W Verheul, Anitra Fielding, Karen So, Wendy Bannister, Emma Dean. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Advances in therapy.
2015 Jun; 32(6):510-22. doi:
10.1007/s12325-015-0214-4. [PMID: 26048134] - Kunal Kapoor, Esha Singla, Bijayani Sahu, Amarjit S Naura. PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Molecular and cellular biochemistry.
2015 Feb; 400(1-2):153-62. doi:
10.1007/s11010-014-2271-4. [PMID: 25404465] - Deanna M Janzen, Daniel Y Paik, Miguel A Rosales, Brian Yep, Donghui Cheng, Owen N Witte, Huseyin Kayadibi, Christopher M Ryan, Michael E Jung, Kym Faull, Sanaz Memarzadeh. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Molecular cancer therapeutics.
2013 Dec; 12(12):2917-28. doi:
10.1158/1535-7163.mct-13-0572. [PMID: 24222661] - C M Nijenhuis, L Lucas, H Rosing, J H M Schellens, J H Beijnen. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2013 Dec; 940(?):121-5. doi:
10.1016/j.jchromb.2013.09.020. [PMID: 24145016] - Shuichi Shimma, Yuki Takashima, Jun Hashimoto, Kan Yonemori, Kenji Tamura, Akinobu Hamada. Alternative two-step matrix application method for imaging mass spectrometry to avoid tissue shrinkage and improve ionization efficiency.
Journal of mass spectrometry : JMS.
2013 Dec; 48(12):1285-90. doi:
10.1002/jms.3288. [PMID: 24338883] - Nigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, Janis Eglitis, Viktor Paramonov, Peter McCormack, Helen Swaisland, Maria Cavallin, Tony Parry, James Carmichael, J Michael Dixon. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Investigational new drugs.
2013 Aug; 31(4):949-58. doi:
10.1007/s10637-012-9922-7. [PMID: 23315029] - Samuel Peña-Llopis, Silvia Vega-Rubín-de-Celis, Arnold Liao, Nan Leng, Andrea Pavía-Jiménez, Shanshan Wang, Toshinari Yamasaki, Leah Zhrebker, Sharanya Sivanand, Patrick Spence, Lisa Kinch, Tina Hambuch, Suneer Jain, Yair Lotan, Vitaly Margulis, Arthur I Sagalowsky, Pia Banerji Summerour, Wareef Kabbani, S W Wendy Wong, Nick Grishin, Marc Laurent, Xian-Jin Xie, Christian D Haudenschild, Mark T Ross, David R Bentley, Payal Kapur, James Brugarolas. BAP1 loss defines a new class of renal cell carcinoma.
Nature genetics.
2012 Jun; 44(7):751-9. doi:
10.1038/ng.2323. [PMID: 22683710] - Rolf W Sparidans, Irene Martens, Liselot B J Valkenburg-van Iersel, Jan den Hartigh, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Jul; 879(21):1851-6. doi:
10.1016/j.jchromb.2011.05.003. [PMID: 21622034]
